Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/EUCTR2010-019643-19-AT
EUCTR2010-019643-19-ATActive, not recruitingNot Applicable

The effect of clopidogrel and prasugrel with and without acetylsalicylic acid (ASA) on hemostatic system activation at the site of plug formation in vivo in man

Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I, Abt.f.Hämatologie u.Hämostaseologie0 sitesStarted: December 21, 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Active, not recruiting
Sponsor
Study OverviewEligibility CriteriaInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional clinical trial of medicinal product

Eligibility Criteria

Sex
Male

Inclusion Criteria

  • •-age between 19 and 50 years
  • •-normal findings on the medical history
  • •-body mass index (BMI) between 15th and 85th percentile of normal
  • •-non-smoking behaviour
  • •Are the trial subjects under 18? no
  • •Number of subjects for this age range:
  • •F.1.2 Adults (18-64 years) yes
  • •F.1.2.1 Number of subjects for this age range
  • •F.1.3 Elderly (>=65 years) no
  • •F.1.3.1 Number of subjects for this age range

Exclusion Criteria

  • •-history of bleeding
  • •-allergy to or contraindication against ASA
  • •-history of or symptoms suggestive for gastrointestinal disease
  • •-abuse of alcoholic beverages
  • •-use of any medication within two weeks before blood sampling.

Investigators

Sponsor
Medizinische Universität Wien, Univ.Klinik f.Innere Medizin I, Abt.f.Hämatologie u.Hämostaseologie

Similar Trials

Active, not recruiting
Not Applicable
Effectiveness of Prasugrel versus Clopidogrel in Subjects with High Platelet Reactivity on Clopidogrel Following Elective Percutaneous Coronary Intervention with Implantation of Drug-Eluting Stent - TACWReduction of composite cardio-vascular end-point in patients who have successfully undergone elective percutaneous coronary intervention with placement of at least one drug-eluting stent.
EUCTR2008-004997-41-DEEli Lilly and Company3,250
Not yet recruiting
Phase 4
Does the dual antiplatelet medication of aspirin and either clopidogrel or prasugrel affect inflammatory and oxidative stress measures in individuals with acute coronary syndrome similarly?
CTRI/2023/07/055349Pt B D Sharma PGIMS Rohtak
Completed
Phase 4
Comparison of clopidogrel and prasugrel as prophylaxis for In-stent protrusion evaluated by optical coherence tomography in patients with ST-segment elevation myocardial infarctioST-segment elevation myocardial infarction
JPRN-UMIN000017732Yokohama city university medical center Cardiovascular center50
Active, not recruiting
Not Applicable
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed - The TRILOGY ACS Study - Trilogy ACSTreatment of Acute Coronary Syndrome in medically managed subjects enrolled within 10 days of the unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) index event.MedDRA version: 9.1Level: LLTClassification code 10051592Term: Acute coronary syndrome
EUCTR2007-005210-39-HUEli Lilly and Company11,200
Active, not recruiting
Phase 1
A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEMI) Who are Medically Managed - The TRILOGY ACS Study - Trilogy ACSTreatment of Acute Coronary Syndrome in medically managed subjects enrolled within 7 days of the unstable angina/non-ST-segment elevation myocardial infarction (UA/NSTEMI) index event.MedDRA version: 9.1Level: LLTClassification code 10051592Term: Acute coronary syndrome
EUCTR2007-005210-39-FREli Lilly and Company11,200
The effect of clopidogrel and prasugrel... | Clinical Trial